Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Meera Mohan

Showing results (41-50 of 62) with videos related to

Pageof 7
Sort By:
Cancer|June 7, 2023
Concomitant deletion of the short arm (del(1p13.3)) and amplification or gain (1q21) of chromosome 1 by fluorescence in situ hybridization are associated with a poor clinical outcome in multiple myelomaMeera Mohan, Zimu Gong, Timothy Cody Ashby, et al.
Journal of the National Cancer Institute|November 9, 2025
Optimizing oncology drug development: systematic review of 22 years of myeloma randomized controlled trialsMaria Mainou, Muatassem Alsadhan, Kalliopi Tsapa, et al.
Blood Advances|June 18, 2024
Outpatient administration of CAR T-cell therapies using a strategy of no remote monitoring and early CRS interventionFateeha Furqan, Vineel Bhatlapenumarthi, Binod Dhakal, et al.
Blood Advances|November 22, 2021
Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myelomaMeera Mohan, Samantha Kendrick, Aniko Szabo, et al.
British Journal of Haematology|December 6, 2023
Chimeric antigen receptor and bispecific T-cell engager therapies in multiple myeloma patients with prior allogeneic transplantationLindsay Hammons, Shabi Haider, Andrew J Portuguese, et al.
Cancers|August 27, 2021
Salvage Autologous Stem Cell Transplantation in Daratumumab-Refractory Multiple MyelomaLakshmi Yarlagadda, Sravani Gundarlapalli, Richa Parikh, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|February 28, 2017
Extensive Remineralization of Large Pelvic Lytic Lesions Following Total Therapy Treatment in Patients With Multiple MyelomaMeera Mohan, Rohan S Samant, Donghoon Yoon, et al.
Future Oncology (London, England)|April 23, 2026
Real-world treatment patterns and outcomes of patients with multiple myeloma initiating elranatamab: results from the ALTITUDE-1 and ALTITUDE-2 retrospective cohort studiesRahul Banerjee, Meera Mohan, Bhavesh Shah, et al.
Blood Cancer Journal|November 7, 2025
Talquetamab in relapsed refractory multiple myeloma: multi-institutional real-world studySamer Al Hadidi, Aniko Szabo, Bhavesh Mohan Lal, et al.
Bone Marrow Transplantation|January 4, 2024
Severity and organ distribution of chronic graft-versus-host disease with posttransplant cyclophosphamide-based versus methotrexate/calcineurin inhibitor-based allogeneic hematopoietic cell transplantationSaurabh Chhabra, James H Jerkins, Kathleen Monahan, et al.
Pageof 7

Showing results (41-50 of 62) with videos related to

Sort By:
Pageof 7
Cancer|June 7, 2023
Concomitant deletion of the short arm (del(1p13.3)) and amplification or gain (1q21) of chromosome 1 by fluorescence in situ hybridization are associated with a poor clinical outcome in multiple myelomaMeera Mohan, Zimu Gong, Timothy Cody Ashby, et al.
Journal of the National Cancer Institute|November 9, 2025
Optimizing oncology drug development: systematic review of 22 years of myeloma randomized controlled trialsMaria Mainou, Muatassem Alsadhan, Kalliopi Tsapa, et al.
Blood Advances|June 18, 2024
Outpatient administration of CAR T-cell therapies using a strategy of no remote monitoring and early CRS interventionFateeha Furqan, Vineel Bhatlapenumarthi, Binod Dhakal, et al.
Blood Advances|November 22, 2021
Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myelomaMeera Mohan, Samantha Kendrick, Aniko Szabo, et al.
British Journal of Haematology|December 6, 2023
Chimeric antigen receptor and bispecific T-cell engager therapies in multiple myeloma patients with prior allogeneic transplantationLindsay Hammons, Shabi Haider, Andrew J Portuguese, et al.
Cancers|August 27, 2021
Salvage Autologous Stem Cell Transplantation in Daratumumab-Refractory Multiple MyelomaLakshmi Yarlagadda, Sravani Gundarlapalli, Richa Parikh, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|February 28, 2017
Extensive Remineralization of Large Pelvic Lytic Lesions Following Total Therapy Treatment in Patients With Multiple MyelomaMeera Mohan, Rohan S Samant, Donghoon Yoon, et al.
Future Oncology (London, England)|April 23, 2026
Real-world treatment patterns and outcomes of patients with multiple myeloma initiating elranatamab: results from the ALTITUDE-1 and ALTITUDE-2 retrospective cohort studiesRahul Banerjee, Meera Mohan, Bhavesh Shah, et al.
Blood Cancer Journal|November 7, 2025
Talquetamab in relapsed refractory multiple myeloma: multi-institutional real-world studySamer Al Hadidi, Aniko Szabo, Bhavesh Mohan Lal, et al.
Bone Marrow Transplantation|January 4, 2024
Severity and organ distribution of chronic graft-versus-host disease with posttransplant cyclophosphamide-based versus methotrexate/calcineurin inhibitor-based allogeneic hematopoietic cell transplantationSaurabh Chhabra, James H Jerkins, Kathleen Monahan, et al.
Pageof 7